These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 22876544)

  • 1. Evaluation and comparison of safety, convenience and cost of administering intravenous pamidronate infusions to children in the home and ambulatory care settings.
    Rush ET; DeHaai K; Kreikemeier RM; Lutz RE
    J Pediatr Endocrinol Metab; 2012; 25(5-6):493-7. PubMed ID: 22876544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of a Modified Pamidronate Protocol for the Treatment of Osteogenesis Imperfecta.
    Palomo T; Andrade MC; Peters BS; Reis FA; Carvalhaes JT; Glorieux FH; Rauch F; Lazaretti-Castro M
    Calcif Tissue Int; 2016 Jan; 98(1):42-8. PubMed ID: 26387692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low doses of pamidronate for the treatment of osteopenia in non-ambulatory children.
    Henderson R
    Dev Med Child Neurol; 2006 Sep; 48(9):708. PubMed ID: 16904013
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteogenesis imperfecta type VI in childhood and adolescence: effects of cyclical intravenous pamidronate treatment.
    Land C; Rauch F; Travers R; Glorieux FH
    Bone; 2007 Mar; 40(3):638-44. PubMed ID: 17127117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time and labor costs associated with administration of intravenous bisphosphonates for breast or prostate cancer patients with metastatic bone disease: a time and motion study.
    Xie F; Hopkins RB; Burke N; Habib M; Angelis CD; Pasetka M; Giotis A; Goeree R
    Hosp Pract (1995); 2014 Apr; 42(2):38-45. PubMed ID: 24769783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Bone and joint diseases in children. Bisphosphonates in osteogenesis imperfecta].
    Yamashita S
    Clin Calcium; 2010 Jun; 20(6):918-24. PubMed ID: 20513950
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of intravenous zoledronic acid in paediatric osteoporosis.
    Brown JJ; Zacharin MR
    J Pediatr Endocrinol Metab; 2009 Jan; 22(1):55-63. PubMed ID: 19344075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of a 1-year treatment with zoledronic acid compared with pamidronate in children with osteogenesis imperfecta.
    Barros ER; Saraiva GL; de Oliveira TP; Lazaretti-Castro M
    J Pediatr Endocrinol Metab; 2012; 25(5-6):485-91. PubMed ID: 22876543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tolerance and effectiveness on pain control of Pamidronate® intravenous infusions in children with neuromuscular disorders.
    Wagner S; Poirot I; Vuillerot C; Berard C
    Ann Phys Rehabil Med; 2011 Sep; 54(6):348-58. PubMed ID: 21840280
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Respiratory failure during infusion of pamidronate in a 3 year-old male with osteogenesis imperfecta: a case report.
    Olson JA
    J Pediatr Rehabil Med; 2014; 7(2):155-8. PubMed ID: 25096867
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta.
    Rauch F; Cornibert S; Cheung M; Glorieux FH
    Bone; 2007 Apr; 40(4):821-7. PubMed ID: 17223617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation.
    Andiran N; Alikasifoglu A; Gonc N; Ozon A; Kandemir N; Yordam N
    J Pediatr Endocrinol Metab; 2008 Jan; 21(1):63-72. PubMed ID: 18404974
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclic pamidronate therapy in children with osteogenesis imperfecta.
    Salehpour S; Tavakkoli S
    J Pediatr Endocrinol Metab; 2010; 23(1-2):73-80. PubMed ID: 20432809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant.
    Torregrosa JV; Fuster D; Monegal A; Gentil MA; Bravo J; Guirado L; Muxí A; Cubero J
    Osteoporos Int; 2011 Jan; 22(1):281-7. PubMed ID: 20229199
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteogenesis imperfecta: anthropometric, skeletal and mineral metabolic effects of long-term intravenous pamidronate therapy.
    Vallo A; Rodriguez-Leyva F; Rodríguez Soriano J
    Acta Paediatr; 2006 Mar; 95(3):332-9. PubMed ID: 16497645
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pamidronate treatment of children with moderate-to-severe osteogenesis imperfecta: a note of caution.
    Alharbi M; Pinto G; Finidori G; Souberbielle JC; Guillou F; Gaubicher S; Le Merrer M; Polak M
    Horm Res; 2009 Jan; 71(1):38-44. PubMed ID: 19039235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low-dose intravenous pamidronate treatment in osteogenesis imperfecta.
    Gökşen D; Coker M; Darcan S; Köse T; Kara S
    Turk J Pediatr; 2006; 48(2):124-9. PubMed ID: 16848111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radiological findings in cyclical administration of intravenous pamidronate in children with osteoporosis.
    Onwuneme C; Abdalla K; Cassidy N; Hensey O; Ryan S
    Arch Dis Child; 2007 Dec; 92(12):1087. PubMed ID: 18032639
    [No Abstract]   [Full Text] [Related]  

  • 19. Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation.
    Rauch F; Munns C; Land C; Glorieux FH
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1268-74. PubMed ID: 16434452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Successful results of pamidronate treatment in children with osteogenesis imperfecta with emphasis on the interpretation of bone mineral density for local standards.
    Poyrazoglu S; Gunoz H; Darendeliler F; Bas F; Tutunculer F; Eryilmaz SK; Bundak R; Saka N
    J Pediatr Orthop; 2008 Jun; 28(4):483-7. PubMed ID: 18520289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.